Additional Comments on the FDA’s Proposed Generic Drug Labeling Rule and an Industry Alternative

View as PDF.

Public Citizen strongly supports the Food and Drug Administration’s proposed rule, which will enable generic drug manufacturers to update product labeling with newly discovered risk information, and we urge the agency to move promptly to finalize the proposal. The industry alternative would exacerbate, rather than solve, the safety problem that the FDA proposal seeks to address.